Add-on etanercept as a treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe cutaneous adverse reaction to drugs. The disease carries considerable morbidity and mortality.

Immunomodulators for SJS/TEN such as systemic corticosteroids and intravenous immunoglobulin (IVIG) have been widely used in clinical practice.

Emerging evidence suggested that tumor necrosis factor-α antagonists on SJS/TEN may help.

This restrospective review found that add-in of etanercept at the time of initiating conventional therapy could be a superior option to:

- accelerate disease recovery
- reduce the high dose and total amount of systemic steroids

References:

https://www.annallergy.org/article/S1081-1206(22)00441-0/fulltext

https://www.annallergy.org/article/S1081-1206(22)00579-8/fulltext